2024-09-18 2025-09-30 2025-09-30 false 15963736 HERBLOOM HEALTH CLINIC LIMITED 86220Specialists medical practice activities iso4217:GBP xbrli:pure 159637362024-09-18 159637362025-09-30 159637362024-09-18 2025-09-30 15963736bus:SmallEntities2024-09-18 2025-09-30 15963736bus:AuditExempt-NoAccountantsReport2024-09-18 2025-09-30 15963736bus:FullAccounts2024-09-18 2025-09-30 15963736core:WithinOneYear2025-09-30 15963736core:AfterOneYear2025-09-30 15963736core:WithinOneYear2024-09-18 2025-09-30 15963736core:AfterOneYear2024-09-18 2025-09-30 15963736core:CurrentFinancialInstruments2025-09-30 15963736core:Non-currentFinancialInstruments2025-09-30 15963736core:CurrentFinancialInstruments2024-09-18 2025-09-30 15963736core:Non-currentFinancialInstruments2024-09-18 2025-09-30 15963736core:LandBuildings2024-09-18 2025-09-30 15963736core:FurnitureFittings2024-09-18 2025-09-30 15963736core:OfficeEquipment2024-09-18 2025-09-30 15963736core:Vehicles2024-09-18 2025-09-30 15963736core:PlantMachinery2024-09-18 2025-09-30 15963736core:OtherPropertyPlantEquipment2024-09-18 2025-09-30 15963736core:LandBuildings2025-09-30 15963736core:PlantMachinery2025-09-30 15963736core:Vehicles2025-09-30 15963736core:FurnitureFittings2025-09-30 15963736core:OfficeEquipment2025-09-30 15963736core:OtherPropertyPlantEquipment2025-09-30 15963736core:Right-of-useAssets2024-09-18 2025-09-30 15963736core:Right-of-useAssets2025-09-30 15963736core:Goodwill2024-09-18 2025-09-30 15963736core:PatentsTrademarksLicencesConcessionsSimilar2024-09-18 2025-09-30 15963736core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-09-18 2025-09-30 15963736core:OtherResidualIntangibleAssets2024-09-18 2025-09-30 15963736core:Goodwill2025-09-30 15963736core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-09-30 15963736core:PatentsTrademarksLicencesConcessionsSimilar2025-09-30 15963736core:OtherResidualIntangibleAssets2025-09-30 15963736dpl:CostSales2024-09-18 2025-09-30 15963736dpl:AdministrativeExpenses2024-09-18 2025-09-30 15963736dpl:DistributionCosts2024-09-18 2025-09-3015963736core:ShareCapital2025-09-30 15963736core:SharePremium2025-09-30 15963736core:RevaluationReserve2025-09-30 15963736core:OtherReservesSubtotal2025-09-30 15963736core:ShareCapitalPreferenceShares2025-09-30 15963736core:CapitalRedemptionReserve2025-09-30 15963736core:OtherCapitalReserve2025-09-30 15963736core:RetainedEarningsAccumulatedLosses2025-09-3015963736core:ShareCapital2024-09-18 2025-09-30 15963736core:SharePremium2024-09-18 2025-09-30 15963736core:RevaluationReserve2024-09-18 2025-09-30 15963736core:OtherReservesSubtotal2024-09-18 2025-09-30 15963736core:RetainedEarningsAccumulatedLosses2024-09-18 2025-09-301596373612024-09-18 2025-09-30 1596373622024-09-18 2025-09-3015963736core:ShareCapital12024-09-18 2025-09-30 15963736core:ShareCapital22024-09-18 2025-09-3015963736core:SharePremium12024-09-18 2025-09-30 15963736core:SharePremium22024-09-18 2025-09-3015963736core:RevaluationReserve12024-09-18 2025-09-30 15963736core:RevaluationReserve22024-09-18 2025-09-3015963736core:RetainedEarningsAccumulatedLosses12024-09-18 2025-09-30 15963736core:RetainedEarningsAccumulatedLosses22024-09-18 2025-09-301596373612024-09-18 2025-09-3015963736core:Non-currentFinancialInstrumentscore:CostValuation2024-09-18 15963736core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:CostValuation2025-09-3015963736core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2024-09-18 15963736core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-09-30 15963736core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-09-30 15963736core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-09-3015963736core:Non-currentFinancialInstruments2025-09-30 15963736core:Non-currentFinancialInstruments2024-09-1715963736bus:Director12024-09-18 2025-09-3015963736bus:Director22024-09-18 2025-09-3015963736bus:PrivateLimitedCompanyLtd2024-09-18 2025-09-30
HERBLOOM HEALTH CLINIC LIMITED
Unaudited Financial Statements
for the period ended 30 September 2025
Company registration number 15963736
(England and Wales)

Company Information

For the period 18 September 2024 to 30 September 2025
Directors Mitchell-Bramble, Coral Mary
Ahmed, Karolina

Registered office 26 Farnborough Avenue
London
E17 6HX

Registered number 15963736

Accountant 2020 ACCOUNTANCY
Bourne Space
Bourne House
23 Hinton Road
Bournemouth
Bournemouth
BH1 2EF

Statement of Financial Position

As at 30 September 2025
Notes
2025
£
£
Current assets
Cash at bank and in hand
650
650
Creditors
Amounts falling due within one year
4
(5,308)
(5,308)
Net current assets (liabilities)
(4,658)
Total assets less current liabilities
(4,658)
Net assets (liabilities)
(4,658)
Capital and reserves
Called up share capital
2
Profit and loss account
(4,660)
Total equity
(4,658)

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 26 May 2026 and are signed on its behalf by:

Mitchell-Bramble, Coral Mary
Mitchell-Bramble, Coral Mary
Director
Ahmed, Karolina
Ahmed, Karolina
Director

Company registration number 15963736

Notes to the Financial Statements

For the period 18 September 2024 to 30 September 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

3. Employees

The average number of employees during the year was 0.

4. Creditors due within one year

2025
£
Directors loan account
4,768
Accruals and deferred income
540
Total
5,308